Dear Ms. Moore:


We acknowledge receipt of your submissions dated May 29, 2002 and September 10, 2002.

These supplemental new drug applications provide for revisions to the **ADVERSE REACTIONS** section of the package insert.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted final printed labeling (package insert submitted September 10, 2002, Medication Guide submitted September 10, 2002). Accordingly, these supplemental applications are approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.
If you have any questions, please call Virginia L. Yoerg, Regulatory Health Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Attachment: FPL dated September 10, 2002
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Debra Birnkrant
10/2/02 03:48:30 PM
NDA 20-978, NDA 20-977